Literature DB >> 6455137

Decreased extrarenal clearance of cefoperazone in hepatocellular diseases.

B Cochet, J Belaieff, A F Allaz, M Rudhardt, L Balant, J Fabre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6455137      PMCID: PMC1401676          DOI: 10.1111/j.1365-2125.1981.tb01139.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

2.  [Pharmacokinetics of a new cephalosporin, cefoperazone].

Authors:  A F Allaz; P Dayer; J Fabre; M Rudhardt; L Balant
Journal:  Schweiz Med Wochenschr       Date:  1979-12-29

3.  Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat.

Authors:  J Fabre; P Blanchard; M Rudhardt
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

4.  In vitro activity of a new semisynthetic cephalosporin: cefoperazone.

Authors:  R Auckenthaler; F A Waldvogel
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

  4 in total
  4 in total

Review 1.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

2.  Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.

Authors:  R G Deeter; M P Weinstein; K A Swanson; J S Gross; L C Bailey
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 4.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.